To clarify the clinical relevance of EGFR status, this study examines the clinicopathologic characteristics and outcomes in a uniform population of Western patients with gastric/GE junction adenocarcinoma enrolled in first-line metastatic chemotherapy trials. This evidence concerns the gene EGFR and gastroesophageal junction adenocarcinoma.